Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees, as per NASDAQ Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to eight new employees, as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the awards included options for 247,850 shares at an exercise price of $35.44 per share. The options have a ten-year term with a four-year vesting schedule. Notably, two employees received additional performance-based options tied to regulatory milestones. Insmed aims to support its mission to transform lives of patients with rare diseases and has a pipeline of investigational therapies.
Positive
- Inducement awards granted to eight new employees reflect growth and expansion potential.
- Options for 247,850 shares indicate investment in employee retention and future performance.
Negative
- None.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was -2.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., April 7, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to eight new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on April 1, 2021 to purchase an aggregate 247,850 shares of Insmed common stock at an exercise price of
Time-based options to purchase an aggregate of 18,290 shares of Insmed common stock were granted to six of the eight new employees. These options have a ten-year term and a four-year vesting schedule, with
Two new employees, Chris Bailey-Kellogg and Karl E. Griswold, each received options to purchase 57,390 shares of Insmed common stock that are subject to time-based vesting on the terms described above, as well as options to purchase 57,390 shares of Insmed common stock that are subject to performance-based vesting. The performance-based options will vest in two equal tranches upon the achievement of certain regulatory milestones.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and Europe to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301263181.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.